Stockscreener 앱 받기
15.43
0.00%
0.07
전일 마감가:
$15.50
열려 있는:
$15.44
하루 거래량:
9,614
Relative Volume:
0.03
시가총액:
$395.35M
수익:
-
순이익/손실:
$11.77M
주가수익비율:
26.67
EPS:
0.5785
순현금흐름:
$-19.23M
1주 성능:
-1.52%
1개월 성능:
+3.82%
6개월 성능:
-38.88%
1년 성능:
+1.64%
1일 변동 폭
$14.88
$15.47
1주일 범위
$14.68
$16.32
52주 변동 폭
$11.56
$29.79
Tourmaline Bio Inc Stock (TRML) Company Profile
명칭
Tourmaline Bio Inc
전화
646-481-9832
주소
27 WEST 24TH STREET, NEW YORK
TRML을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
15.25 | 395.35M | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.02 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.72 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
536.00 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.70 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
222.79 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-23 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-11-11 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-15 | 개시 | Jefferies | Buy |
| 2023-12-04 | 재개 | H.C. Wainwright | Buy |
| 2023-11-17 | 개시 | Truist | Buy |
| 2023-10-31 | 개시 | Guggenheim | Buy |
| 2023-10-25 | 개시 | Piper Sandler | Overweight |
| 2022-10-20 | 개시 | H.C. Wainwright | Buy |
| 2022-07-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
모두보기
Tourmaline Bio Inc 주식(TRML)의 최신 뉴스
Contrasting Fennec Pharmaceuticals (NASDAQ:FENC) and VectivBio (NASDAQ:VECT) - Defense World
Tourmaline Bio’s Pacibekitug: A Promising IL-6 Inhibitor for ASCVD with Strong Buy Rating - TipRanks
Raymond James Financial Inc. Takes Position in Commercial Vehicle Group, Inc. (NASDAQ:CVGI) - Defense World
Barclays PLC Increases Position in Chicago Atlantic Real Estate Finance, Inc. (NASDAQ:REFI) - Defense World
Barclays PLC Acquires 5,175 Shares of Tile Shop Holdings, Inc. (NASDAQ:TTSH) - Defense World
Barclays PLC Purchases Shares of 24,107 Grail, Inc. (NASDAQ:GRAL) - Defense World
Barclays PLC Acquires 42,792 Shares of MicroVision, Inc. (NASDAQ:MVIS) - Defense World
Tourmaline Bio (TRML) to Release Quarterly Earnings on Monday - Defense World
FY2025 EPS Estimates for Tourmaline Bio Decreased by Analyst - Defense World
Chardan Capital Raises Earnings Estimates for Tourmaline Bio - Defense World
FY2025 EPS Estimates for Tourmaline Bio Raised by Analyst - Defense World
Tourmaline Bio Q2 EPS Estimate Decreased by HC Wainwright - Defense World
Analysts Set Expectations for Tourmaline Bio Q2 Earnings - Defense World
HC Wainwright Predicts Tourmaline Bio Q2 Earnings - Defense World
Wells Fargo & Company MN Boosts Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio Reports Q1 2025 Financial Results - TipRanks
Tourmaline Bio’s (TRML) “Buy” Rating Reaffirmed at Chardan Capital - Defense World
Tourmaline Bio (NASDAQ:TRML) Receives “Buy” Rating from HC Wainwright - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Barclays PLC - Defense World
Invesco Ltd. Buys Shares of 15,602 Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Invesco Ltd. Purchases 1,181 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
CVS Health (NYSE:CVS) Price Target Raised to $71.00 - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of “Buy” from Brokerages - Defense World
Tourmaline Bio, Inc. SEC 10-Q Report - TradingView
Tourmaline (TRML) Projects Financial Stability into Late 2027 | TRML Stock News - GuruFocus
Tourmaline (TRML) Anticipates Key Data from Phase 2 Trial of Pacibekitug | TRML Stock News - GuruFocus
Tourmaline Bio, Inc. Confirms Progress in Phase 2 TRANQUILITY Trial and Financial Position Ahead of Key Data Readout - Nasdaq
Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Tourmaline Bio Advances Key Cardiovascular Trial With $275M War Chest: Q2 Results Coming - Stock Titan
Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Legal & General Group Plc - Defense World
Thyroid Eye Disease Treatment Market Size (7MM) was ~USD 1,993 - openPR.com
Palantir Technologies (PLTR) Receives a Sell from RBC Capital - The Globe and Mail
As the Market Fluctuates in Response to President Donald Trump's Tariffs, What Stocks Are Safe? - The Globe and Mail
Graves Disease Treatment Market 2034: EMA, PDMA, FDA Approvals, - openPR.com
Chardan Capital Weighs in on Tourmaline Bio FY2025 Earnings - Defense World
Best Stock to Buy Right Now: Costco vs. Realty Income - The Globe and Mail
Nasdaq (NDAQ) Gets a Buy from Barclays - The Globe and Mail
AGNC Investment Expects to Capitalize on Wide Spreads. But Is the High-Yield Dividend Stock a Buy? - The Globe and Mail
Chardan Capital Begins Coverage on Tourmaline Bio (NASDAQ:TRML) - Defense World
Ready to Jump After Recent Trade: Tourmaline Bio Inc (TRML) - Sete News
An analyst sees good growth prospects for New Fortress Energy Inc (NFE) - Sete News
TRML Stock Sees Surge of Approximately 19.36% in Last Five Days - knoxdaily.com
Chardan sets $70 target on Tourmaline Bio, cites lead asset By Investing.com - Investing.com Canada
Biogen (BIIB) to Release Quarterly Earnings on Thursday - Defense World
Cantor Fitzgerald maintains Overweight on Tourmaline Bio stock By Investing.com - Investing.com Canada
Chardan Capital Initiates Coverage of Tourmaline Bio (TRML) with Buy Recommendation - MSN
Investing in Tourmaline Bio Inc (TRML) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
BARK Inc (BARK) did well last session? - uspostnews.com
STRL (Sterling Infrastructure Inc) has impressive results - uspostnews.com
Chardan Initiates Tourmaline Bio at Buy With $70 Price Target - marketscreener.com
Alliancebernstein L.P. Has $263,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio Inc (TRML) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tourmaline Bio Inc 주식 (TRML) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kulkarni Sandeep Chidambar | CEO |
Aug 16 '24 |
Buy |
13.79 |
5,221 |
71,998 |
5,221 |
0.17%
1.60%
자본화:
|
볼륨(24시간):